Menu
 
Research menu
Jump to menu

Publications:  Dr Vittoria Lombardi

Lombardi V, Carassiti D, Giovannoni G, Lu CH, Adiutori R, Malaspina A(2020). The potential of neurofilaments analysis using dry-blood and plasma spots. Scientific Reports vol. 10, (1)
10.1038/s41598-019-54310-y
Gray E, Oeckl P, Amador MDM, Andreasson U, An J, Blennow K, Bowser R, De Schaepdryver M et al.(2020). A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotroph Lateral Scler Frontotemporal Degener1-7.
10.1080/21678421.2020.1779300
Lombardi V, Bombaci A, Zampedri L, Lu C-H, Malik B, Zetterberg H, Heslegrave AJ, Rinaldi C et al.(2020). Plasma pNfH levels differentiate SBMA from ALS. J Neurol Neurosurg Psychiatry vol. 91, (2) 215-217.
10.1136/jnnp-2019-320624
Leoni E, Bremang M, Mitra V, Zubiri I, Jung S, Lu CH, Adiutori R, Lombardi V et al.(2019). Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis. Scientific Reports vol. 9, (1)
10.1038/s41598-019-40632-4
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56425
Lombardi V, Carassiti D, Giovannoni G, Lu CH, Adiutori R, Malaspina A(2019). Theme 7 Pre-clinical therapeutic strategies. Amyotrophic lateral sclerosis & frontotemporal degeneration vol. 20, 217-245.
10.1080/21678421.2019.1646995
Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A(2019). Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration vol. 20, (7-8) 538-548.
10.1080/21678421.2019.1646769
Gold J, Rowe DB, Kiernan MC, Vucic S, Mathers S, van Eijk RPA, Nath A, Garcia Montojo M et al.(2019). Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration vol. 20, (7-8) 595-604.
10.1080/21678421.2019.1632899
Bombaci A, Lombardi V, Malaspina A, Zampedri L, Querin G, Martinelli I, Bertolin C, Lu C et al. (2019). Plasma biomarkers point to muscle damage as a primary component of Kennedy's disease. EUROPEAN JOURNAL OF NEUROLOGY. vol. 26, 823-823.
Lombardi V, Querin G, Ziff OJ, Zampedri L, Martinelli I, Heller C, Foiani M, Bertolin C et al.(2019). Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology vol. 92, (11) E1205-E1211.
10.1212/WNL.0000000000007097
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58927
Zubiri I, Lombardi V, Bremang M, Mitra V, Nardo G, Adiutori R, Lu CH, Leoni E et al.(2018). Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Molecular Neurodegeneration vol. 13, (1)
10.1186/s13024-018-0292-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/51043
Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A(2018). Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Annals of Neurology vol. 84, (1) 130-139.
10.1002/ana.25276
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58985
Ziff O, Lombardi V, Zampedri L, Querin G, Bertolin C, Greensmith L, Hanna M, Zetterberg H et al. (2018). Muscle and neuronal peripheral biomarkers for spinal and bulbar muscle atrophy: muscle holds more promise. NEUROMUSCULAR DISORDERS. vol. 28, S26-S26.
10.1016/S0960-8966(18)30367-5
Rosenstock TR, de Brito OM, Lombardi V, Louros S, Ribeiro M, Almeida S, Ferreira IL, Oliveira CR et al.(2011). FK506 ameliorates cell death features in Huntington’s disease striatal cell models. Neurochemistry International vol. 59, (5) 600-609.
10.1016/j.neuint.2011.04.009
Return to top